Corporate Banner
Satellite Banner
AgriGenomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Rhenovia Pharma Secures Series B Funding

Published: Thursday, February 13, 2014
Last Updated: Thursday, February 13, 2014
Bookmark and Share
The company raises EUR 540,000 (USD 738,000) from historical shareholders to expand its staff.

Rhenovia Pharma has announced that it has raised EUR 540,000 (USD 738,000) from its historical shareholders in a second round of funding.

Founded in 2007, Rhenovia is the world leader in biosimulation of the central nervous system. The company uses its unique technology to create computer simulators that predict the effect of molecules both on healthy patients and others living with conditions such as Alzheimer's disease, Parkinson's disease, epilepsy and depression.

The simulators considerably reduce the need for animal testing. They have numerous applications in the pharmaceutical and agrifood industries and within civilian and military security (neurotoxicity).

In 2009, Rhenovia obtained initial funding from a pool of investors drawn from the Alsace Business Angels and the SODIV fund providing support to SMEs in the Alsace region of France.

The second-round funding of EUR 540,000 announced today came from historical investors. The funds provide a boost to Rhenovia's capital and the means for it to add to its team of staff, particularly in the areas of marketing and therapeutic applications.

“The unfailing support of our historical shareholders has helped us to become the world leader in biosimulation of the central nervous system and to sign our first contracts with industrial partners,” said Dr Serge Bischoff, co-founder and CEO of Rhenovia. “This second round of funding is key to building our business development.”

Third-round funding planned for 2014

Rhenovia plans to complete a third round of funding of EUR 2 million in 2014. This will be open to new investors, particularly family offices. To date the company has largely self-funded its growth. It now intends to step up development across the three key markets that it already services: pharmaceutical, agrifood and neurotoxicity. Each of these three sectors has strong growth potential.

By using Rhenovia's technology, the pharmaceutical industry can identify new drug candidates and shorten lead times for development, reducing the costs of R&D. The technology also helps in anticipating risk (of side effects or interactions with other molecules, for example). As a result, it can reduce the rate of clinical stage failure. The health care and financial stakes are therefore considerable.

In the field of agrifood, Rhenovia's simulators help in the study of how the properties of foodstuffs, neutraceuticals and food supplements affect the central nervous system, contributing to R&D in the sector and to the validation of alleged health benefits. Another challenge is to improve the prevention of neurodegenerative disorders such as Alzheimer's and Parkinson's diseases.

Rhenovia's technology can also measure the effects of neurotoxic agents such as pesticides, nanoparticles, industrial emissions and chemical weapons. It may also help in the development of antidotes to poison gas, making it of key interest to stakeholders in civil and military protection.

Rhenovia now has client contracts in each of these three markets.

Rhenovia provides high-value added consultancy services based on the use of its computer simulators, the development of new, bespoke simulators and licensing for new technologies.

The funding raised in 2014 should enable a rapid increase in Rhenovia's rate of business development. The company has particular plans to supplement its service offering, structuring it to suit each of its target markets with the intention of capturing a significant share of the international market for biosimulation of the central nervous system.

This market is showing strong growth. According to Rhenovia, it is expected to be worth several tens of millions of euros in 2018.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Invasive Species Could Cause Billions in Agriculture Damages
Invasive insects and pathogens could be a multi-billion-dollar threat to global agriculture and developing countries may be the biggest target, according to a team of international researchers.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Scoliosis Linked to Disruptions in Spinal Fluid Flow
A new study in zebrafish suggests that irregular fluid flow through the spinal column brought on by gene mutations is linked to a type of scoliosis that can affect humans during adolescence.
More Research Needed to Ensure Gene Drive Safety
Gene-Drive modified organisms are not ready to be released into environment a new report calls for more research and robust assessment.
Genetic Basis of Petunia Variation Uncovered
A large international team of researchers, including scientists from Wageningen University, have now sequenced the entire genome of two different wild petunia species, and published this in the important scientific journal Nature Plants.
Genetically Engineered Crops Are Safe
Distinction between genetic engineering and conventional plant breeding becoming less clear, says new report on GE crops.
Breeding More Climate Resilient Brassicas
Scientists at the John Innes Centre have discovered how a gene that helps determine plant flowering time could help us breed better brassicas in the face of climate change.
One Step Closer To Developing Non-Allergenic 'Super' Peanuts
Scientists from The University of Western Australia have joined a global research team that have identified genes in peanuts that when altered will be able to prevent an allergic response in humans.
Developing Non-Allergenic 'Super' Peanuts
Scientists from The University of Western Australia have joined a global research team that have identified genes in peanuts that when altered will be able to prevent an allergic response in humans.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!